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Natural killer (NK) cells contribute to the first line of defense against viruses and to the
control of tumor growth and metastasis spread. The discovery of HLA class I specific
inhibitory receptors, primarily of killer Ig-like receptors (KIRs), and of activating receptors
has been fundamental to unravel NK cell function and the molecular mechanisms
of tumor cell killing. Stemmed from the seminal discoveries in early ‘90s, in which
Alessandro Moretta was the major actor, an extraordinary amount of research on KIR
specificity, genetics, polymorphism, and repertoire has followed. These basic notions on
NK cells and their receptors have been successfully translated to clinical applications,
primarily to the haploidentical hematopoietic stem cell transplantation to cure otherwise
fatal leukemia in patients with no HLA compatible donors. The finding that NK cells
may express the PD-1 inhibitory checkpoint, particularly in cancer patients, may allow
understanding how anti-PD-1 therapy could function also in case of HLA class Ineg
tumors, usually susceptible to NK-mediated killing. This, together with the synergy of
therapeutic anti-checkpoint monoclonal antibodies, including those directed against
NKG2A or KIRs, emerging in recent or ongoing studies, opened new solid perspectives
in cancer therapy.
Keywords: HLA class I, killer immunoglobulin-like receptors, KIR ligands, inhibitory checkpoints, NK alloreactivity,
NK cell education, polymorphism
INTRODUCTION
The groundbreaking discoveries made by Alessandro Moretta left a very big footprint in
Immunology, and, more generally, in Medicine (1, 2). Indeed, also now that “the music is over”
(3) the Alessandro’s legacy will remain, witnessed by the many human lives saved thanks to his
seminal studies and his continuous efforts to translate discoveries to the benefit of patients with
leukemia or solid tumors.
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Since the beginning of his scientific career, Alessandro
focused his research on two different issues that revealed to be
fundamental for his future major accomplishments: on one side,
the generation of monoclonal antibodies (mAbs) to functional
surface molecules expressed by human T cells, and on the
other side, the development of a highly efficient T cell cloning
technique allowing clonal growth of virtually 100% T cells
(4). While these early studies provided important information
on co-receptor molecules inducing accessory signals for T cell
activation and on the frequency and subset distribution of T
cells endowed with given functional capabilities, they offered an
invaluable tool for the subsequent development of techniques
suitable for efficient cloning of natural killer (NK) cells. In
turn, NK cell clones were fundamental for the discovery of
both killer immunoglobulin-like receptors (KIRs) and natural
cytotoxicity receptors (NCRs), the two most important steps
toward unraveling NK cell function.
General View on NK Cells
Notably, although NK cells were discovered in the mid ‘70s, the
molecular mechanism(s) by which they discriminate between
tumor and healthy cells remained obscure for long time. In
late ‘80s, the “missing self-hypothesis,” proposed by Karre and
Ljunggren, inspired the subsequent seminal discoveries in mice
and humans in early ‘90s (5). The “missing self-hypothesis”
stemmed from the observation that NK cells could kill a
lymphoma cell line that had lost major histocompatibility (MHC)
class I surface molecules, while the original MHC class Ipos
were resistant to lysis. A conceivable interpretation was that
NK cells are able to sense the absence of “self ” MHC class I
molecules on target cells. Indeed, MHC class I specific inhibitory
receptors were discovered in parallel in humans and mice (6, 7).
Surprisingly, human and mice receptors were found to belong
to distinct molecular families, namely the Ig-superfamily and
the lectin family, respectively. The inhibitory signals generated
by the engagement with their MHC class I ligands resulted in
NK cell inactivation. The prototypes of human leukocytes (HLA)
class I specific receptors were two highly homologous molecules
(p58.1 and p58.2) (8, 9), expressed by partially overlapping NK
cell subsets. They were shown to recognize allotypic determinants
shared by the two main groups of HLA-C alleles. While
KIRs are expressed at late stages of NK cell differentiation,
more immature NK cells express another important inhibitory
receptor, the CD94:NKG2A heterodimer, specific for HLA-E
(10). CD94:NKG2A is the first HLA class I specific receptor
to be expressed during NK cell differentiation. At a further
differentiation stage, it may be co-expressed with KIR(s), while
it is lost by the most mature NK cells which express KIR(s)
only (11). Notably, the pool of mature NK cells expresses at
least one inhibitory receptor for self-HLA class I (whether KIR
or NKG2A), thus avoiding autoreactivity. The very few NK
cells lacking self-reactive receptors are anergic. This status is
acquired during NK cell maturation by a process referred to
as NK cell “licensing” or “education” (12, 13). Although HLA
class I specific inhibitory receptors were fitting with the “missing
self-hypothesis,” the understanding of the actual molecular
mechanism(s) regulating NK cell function was incomplete, as the
“on” signals inducing NK cell activation in the process of tumor
cell lysis were unknown.
Again, the use of NK cell clones and the generation and
selection of mAbs capable of modulating NK cell function
allowed the identification of three novel activating receptors:
NKp46 (14, 15), NKp44 (16, 17), and NKp30 (18), collectively
named NCRs (19), playing a major role in tumor cell recognition
and killing. In addition, Alessandro identified the function
of other surface molecules acting as co-receptors, including
p75/AIRM1, IRp60, 2B4, NTBA, and NKp80 (20–25), and could
also determine the activating function of DNAM-1 (CD226)
and its corresponding ligands (namely PVR and Nectin-2)
(26). It became evident that NK cell activation is dependent
on an array of receptors and co-receptors that interact with
ligands overexpressed or expressed de novo on “stressed”
cells and on tumor-transformed or virus-infected cells. While,
in an autologous environment, healthy cells express HLA
class I molecules that generate inhibitory signals via KIR or
NKG2A, tumor- or virus-infected cells may display HLA down-
regulation, allowing NK cell triggering via activating receptors
and consequent target cell killing. In the case of viral infections
that do not down-regulate HLA class I, the susceptibility to
NK-mediated killing may be related to viral peptides that, upon
binding to HLA molecules, could impair KIR engagement.
Altogether, these findings revealed that NK cell activation
is under the control of inhibitory and activating receptors and
their ligands on target cells, and thus receptor/ligand pairs
could represent true checkpoints in the regulation of NK cell
function (27). Notably, an important mechanism of tumor escape
is the down-regulation of activating NK receptor expression,
thus eluding the NK-mediated control of tumor growth and
metastatic spread (28–30).
In humans, twomainNK cell subsets were originally identified
on the basis of the intensity of CD56 surface expression. The
two subsets are differently distributed in blood and tissues:
CD56dim are largely predominant in peripheral blood (PB), while
CD56bright are much more abundant in tissues. CD56bright NK
cells are relatively immature, express NKG2A and not KIR, are
poorly cytolytic, secrete cytokines (primarily IFN-γ and TNF-
α), and undergo intensive proliferation in response to IL-2 or
IL-15. In contrast, CD56dim NK cells express NKG2A and/or
KIR, are mature, display a strong cytolytic activity and cytokine
secretion capability rapidly upon activation. Remarkably, on the
basis of the surface expression of NKG2A and/or KIR, and
other markers, CD56dim NK cells could be further subdivided in
different subsets representative of distinct differentiation stages
characterized by the progressive decrease of the proliferative
capacity, paralleled by an increase of cytolytic activity (11,
31). The most mature, terminally differentiated, NK cells are
KIRpos CD57pos CD16bright and may express the HLA-E specific
activating receptor NKG2C. As recently revealed (also with the
Alessandro’s contribution), NKG2Cpos cells undergo expansion
in CMV infections, displaying adaptive features andmemory-like
function (32–35).
During the last decade, cells belonging to the innate lymphoid
cells (ILCs) were identified. They share with NK cells a common
ID2pos lymphoid precursor. Absent or infrequent in PB of healthy
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individuals, they reside primarily in mucosal tissues, skin, and
lymphoid organs (e.g., tonsils), where they participate to innate
defense against pathogens and to tissue repair/regeneration (36–
38). They are referred to as “helper” ILC, being non-cytolytic and
producing typical sets of cytokines. While they will not be further
discussed here, it is noteworthy that an important subset of ILC3
(the NCRpos ILC3) is characterized by the expression of NCR,
the activating receptors originally described and characterized
by Alessandro.
NK cells can migrate from blood to tissues or lymphoid
organs. Their traffic is regulated by chemokines and their
corresponding receptors, addressing different NK subsets to
specific compartments or inflammatory sites. In addition, since
CD34pos precursors, capable of differentiating toward NK cells,
have been detected in tissues including liver (39), tonsils (40),
thymus (41), and decidua (42), it is likely that some of the
tissue resident NK cells may undergo differentiation from
these precursors and, under the influence of specific tissue
microenvironment, acquire unique functional properties.
While NK cells mediate a strong anti-tumor activity, their
effectiveness may be greatly compromised by the suppressive
microenvironment of different tumors. Suppression is mediated
by a number of mechanisms, including release of soluble factors
by tumor cells and by cells present in the microenvironment that
have been attracted and/or “conditioned” by tumor cells. These
cells include M2 macrophages, myeloid-derived suppressor
cells (MDSC), T-reg and stromal cells (30). In addition,
hypoxia, frequently occurring in tumor lesions, also contributes
to the inhibition of immune effector cells. In the case of
NK cells, the principal effect is the down-regulation of the
activating NK receptors, thus rendering NK cells “disarmed”
and unable to recognize specific ligands on tumor cells. Another
related tumor-induced mechanism playing an important role
in tumor escape is the expression of inhibitory checkpoints,
primarily PD-1, in NK (and T) cells, and of the corresponding
ligands in tumor cells (PD-L1 and PD-L2). The PD-1/PD-L1
interaction has been shown to induce NK cell inactivation (43).
Notably, PD-1 expression in NK cells has been reported and
functionally analyzed by Alessandro and coworkers (44). PD-
1 will be briefly discussed, in the frame of novel immune-
based strategies that appear very promising in tumor therapy.
The important role of NK cells and their receptors in defense
against tumors and leukemia is also witnessed by the great
success achieved in the T-depleted, haploidentical hematopoietic
stem cell transplantation (haplo-HSCT) setting to cure high-risk
leukemia. The unthinkable benefit of this therapeutic approach
is primarily related to the graft-vs.-leukemia effect of donor NK
cells, arising from grafted stem cells and/or infused with the graft.
Thus, in less than 3 decades, a cell of the innate immunity
that was substantially underscored (45) became an important
tool to successfully treat otherwise incurable leukemia. Many
of these major therapeutic achievements are based on seminal
Alessandro’s discoveries illustrated in this review.
While the main focus of our applied researches has been
the involvement of KIRs in defense against tumors and
leukemia, it is important to underline that KIRs and their
polymorphisms have been shown to play a relevant role
also in inflammation, infection, autoimmune diseases, and
reproduction (46–48).
MILESTONES IN THE DISCOVERY OF HLA
SPECIFIC RECEPTORS IN EARLY ‘90S
In late ‘80s, Alessandro Moretta came to Genoa from Lausanne
with a “very special cell line”: the hybridoma producing GL183
mAb. Through this mAb he identified a novel 58-kD surface
molecule expressed on a subset of NK cells and capable of
modulating NK cell cytolytic function (8). The paper describing
this molecule was published in 1990 and this was the beginning
of a new exciting era that led to the discovery of various
HLA class I specific receptors, using the same approach
based on mice immunization with NK cell clones and on the
hybridoma technology. Soon thereafter, by immunizing mice
with a GL183neg NK cell clone, EB6 mAb was selected for
its ability to react with a molecule distinct from GL183 but
sharing most of its characteristics, as revealed by phenotypic,
biochemical, and functional studies (9). Notably, the reactivity
of the two mAbs allowed the identification of four NK cell
subsets that could be extremely variable in terms of relative
percentages among different individuals. Both mAbs could
inhibit the cytolytic activity of selected NK clones (expressing
either GL183 or EB6) in redirected killing assays, using the
FcγRpos murine P815 target cell line. Interestingly, a striking
correlation existed between the EB6pos GL183neg phenotype of
NK cell clones and their ability to lyse normal allogeneic cells,
such as PHA-blasts, in a previously defined type of alloreactivity
(i.e., stimulator/responder combination in mixed lymphocyte
reaction, MLR), termed “1 anti-A” or “group 1” (49–51). In
the same years the seminal study by Ljunggren and Karre
(an elaboration of the Karre’s PhD thesis in early ‘80s) was
published, formulating the “missing self ” hypothesis (5). In
humans, p58 molecules appeared to fit with this proposal,
rendering NK cells capable of self/non-self discrimination. Then
a close relationship could be determined between the expression
of EB6- and GL183-reactive molecules, termed p58.1 and p58.2,
respectively, and their specificity for different HLA-C alleles
(52–54). Evidence was provided that HLA-C∗03 and HLA-C∗04
conferred selective protection from GL183pos and from EB6pos
NK clones respectively (52, 55). These two specificities were
extended to a series of HLA-C alleles related to HLA-C∗03,
characterized by Ser77-Asn80, and those related to HLA-C∗04,
characterized by Asn77-Lys80 (56). These two distinct groups
of HLA-C alleles encompass virtually all the expressed HLA-C
molecules. Thus, EB6pos GL183neg “group 1” NK clones could
lyse allogeneic cells expressing only HLA-C alleles with Ser77-
Asn80 motif, while EB6neg GL183pos “group 2” NK clones were
alloreactive against target cells expressing only HLA-C alleles
with Asn77-Lys80 motif. Importantly, treatment of NK clones
with mAbsmasking p58molecules resulted in the killing of HLA-
C protected cells, showing that this inhibitory receptor/ligand
interaction was responsible for the blocking of target cell lysis
(55). Consistent with these notions, NK clones co-expressing
p58.1 and p58.2 molecules were inhibited by the interaction
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with any allogeneic target cells, thus being unable of any type
of alloreactivity (57). In the same years, NKB1 was described
as a 70 kDa glycoprotein, whose expression was detected by
DX9 mAb, and DX9pos NK clones recognized a group of HLA-
B alleles carrying the Bw4 public epitope (58, 59). Thus, analysis
of NK cell clones, derived not only from different donors but
also from single donors, allowed the detection of the great NK
cell heterogeneity with extremely variable patterns of expression
and co-expression of the various receptors with different HLA
specificities. In 1992, studying in different donors the NK cell
repertoire related to the ability to lyse allogeneic cells, five
distinct allospecificities were described (60). While “group 1” and
“group 2” had been previously defined, “group 3” could be later
explained by the expression of p70 alone (detected by Z27 mAb),
and “group 5” by the expression of both p58.1 and p70 (57). These
data supported the notion that each HLA class I specific receptor
could be physically and functionally independent (57, 61).
Another important piece of history was added by the evidence
that EB6 and GL183 mAb could also recognize activating
receptors, named p50.1 and p50.2, respectively, according to their
molecular mass (62). Subsequently, another activating receptor,
termed p50.3, was identified by three PAX mAbs and was not
stained by either GL183 or EB6 mAb (63). Differently from
p58 molecules, found in all individuals, p50 receptors could be
detected only in some donors. A crucial step was represented
by the identification of the cDNAs coding for these receptors,
demonstrating that they belong to the same molecular family
(64). The p58 and p50 molecules were highly homologous
in their extracellular regions formed by 2 Ig-like domains,
while major differences existed in their transmembrane and
cytoplasmic portions. Notably, while in p58 the transmembrane
region included only non-polar residues, in p50 it contained
the charged amino acid Lys. Moreover, whereas p58 displayed a
76–84 amino acid cytoplasmic tail containing two YxxL motifs
(D/Ex8D/ExxYxxLx26YxxL), later referred to as immunoreceptor
tyrosine-based inhibitory motifs (ITIMs), p50 was characterized
by a shorter tail (39 amino acids) lacking YxxL (64–66). The
cDNA encoding the Bw4 specific receptors, named NKB1/p70,
was also identified, revealing that its extracellular region was
composed by 3 Ig-like domains and that its cytoplasmic tail
included ITIMs (65, 67). All the genes coding for these receptors
were mapped on chromosome 19q13.4. Concomitantly, cloning
of CD94-encoding gene revealed that CD94 is a type II protein
of the C-type lectin superfamily and that this gene is located
on chromosome 12 (68). NK cell clones expressing CD94bright
phenotype did not lyse cell lines transfected with different HLA
class I alleles, and their cytotoxicity could be restored by mAb-
mediated masking of CD94 or HLA class I (69). Moreover, a
functional ambivalence of CD94-associated surface antigens was
described (see below) (70). Finally, an additional inhibitory NK
receptor of the Ig-like superfamily was identified to be specific
for HLA-A∗03 and -A∗011 allotypes (71, 72). In our laboratory
the production of Q66 mAb allowed the characterization of this
receptor, which appeared to be a disulphide-linked dimer and
was termed p140. Importantly, KIRs (and NKG2A) were also
detected in a subset of CD8pos αβ T cells (73) in which they could
interfere with TCR-mediated cell activation. These T cells were
found to represent oligoclonally or monoclonally expanded cell
populations (74). Subsequent studies revealed that such KIRpos
CD8pos cells were HLA-E restricted (75, 76).
All these data, published between 1990 and 1996, represent
true milestones for our present knowledge of the HLA specific
receptors. Alessandro pioneered these studies with the discovery
of p58 receptors and gave a fundamental contribution to most of
the other major findings. Tracking all the rational steps leading
to these discoveries in a seminal Alessandro’s review, published
in Annual Review in Immunology in 1996, has been for us
both moving and impressive (7). Indeed, his contributions still
represent a complete and modern insight on NK cell biology.
KIR NOMENCLATURE
Different research groups started to work on the NK cell
recognition of HLA class I molecules, therefore receptors and
encoding cDNAs were named differently, so that the need
for a common nomenclature arose. Thus, in late ‘90s, the
acronym KIR (killer-cell inhibitory receptor) was proposed
to indicate the members of this novel family (77). Then,
following the experimental evidences that some KIR receptors
were able to transduce activating signals, it was suggested to
preserve the KIR acronym simply changing the meaning of
“I” into “immunoglobulin-like.” The KIR nomenclature was
designed in order to reflect the structure and the function
of the encoded molecules, as well as the nucleotide sequence
similarity among the different KIR family members. Thus, the
first 2 digits following KIR correspond to the number of the
extracellular domains (2D and 3D), while the third digit provides
information on the length of the cytoplasmic tail (L or S)
and consequently reveals the protein function (inhibitory or
activating, respectively). Moreover, the two pseudogenes are
indicated with the letter “P” (namely, KIR2DP1 and KIR3DP1)
(78). The establishment of a centralized, publicly accessible
KIR database (IPD-KIR), collecting all the officially recognized
nucleotide and protein sequences, has been of great help to all the
immunologists involved in the study of KIR gene polymorphism
(79). Temporally, the first KIR Nomenclature report coincided
with the first release of the IPD-KIR database. Finally, like other
immune cell surface proteins, a CD number has been assigned to
KIR proteins (namely the CD158 series).
Reconnecting with what has been described in the previous
paragraph, it is possible to attribute the KIR nomenclature
to the molecules with the “old” denomination. Thus,
p58.1 and p50.1 correspond to KIR2DL1 and KIR2DS1,
p58.2 and p50.2 to KIR2DL2/L3 and KIR2DS2, p50.3
to KIR2DS4, NKB1/p70 to KIR3DL1, and p140/NKAT4
to KIR3DL2.
KIR GENES DISPLAY AN EXTRAORDINARY
LEVEL OF POLYMORPHISM
KIR gene family is characterized by an extraordinary
high degree of diversity, which arises from variability
in KIR gene content, due to differences in both
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presence/absence (P/A) of KIR genes and KIR gene
copy number, and from allelic polymorphism (80–89).
Several strategies have been developed to analyze KIR
repertoires, including approaches able to analyze P/A of
the different KIR genes, KIR gene copy number variations,
and, more recently, a “whole” KIR allele typing by next
generation sequencing (NGS) approach (87, 90–100)
underlining the huge interest of the immunologists in the
KIR field.
KIR Haplotypes
As previously mentioned, KIR gene family has been mapped
on chromosome 19q13.4 where KIR genes, each spanning ∼10–
16 kb, are tightly arranged in a head-to-tail orientation. This
family consists of 13 genes (KIR2DL1, KIR2DL2/L3, KIR2DL4,
KIR2DL5A,KIR2DL5B,KIR2DS1,KIR2DS2,KIR2DS3,KIR2DS4,
KIR2DS5, KIR3DL1/S1, KIR3DL2, KIR3DL3) and 2 pseudogenes
(KIR2DP1, and KIR3DP1) (82, 101, 102). With few exceptions,
KIR haplotypes can be divided in two regions, termed
centromeric (Cen) and telomeric (Tel), by the presence of
a recombination hot spot (86, 87, 89). Four genes, named
framework genes (i.e., KIR3DL3, KIR3DP1, KIR2DL4, and
KIR3DL2), mark the beginning and the end of these two
regions. Based on the different number and kind of KIR
genes present, three different centromeric regions (referred to
as Cen-A, Cen-B1, and Cen-B2) and two different telomeric
regions (namely Tel-A and Tel-B) have been identified
(Figure 1A). Despite the high level of KIR gene content
variability described, two main groups of KIR haplotypes,
termed as “A” and “B,” have been identified (46, 80, 87, 102–
106). The A haplotypes have a fixed gene content and are
composed by Cen-A and Tel-A regions (Figures 1A,B). They
include inhibitory KIR genes coding for receptors recognizing
HLA-C (KIR2DL1 and KIR2DL3), HLA-B (KIR3DL1), HLA-
A (KIR3DL2), and HLA-G (KIR2DL4) molecules and only
one activating KIR (KIR2DS4) that, in some A haplotypes,
does not code for a surface receptor (102). The remaining
KIR haplotypes are collectively referred to as B haplotypes,
and comprise haplotypes carrying Cen-A/Tel-B, Cen-B/Tel-
A, and Cen-B/Tel-B combinations (Figure 1B). They are
characterized by the presence of at least one of the following
KIR genes: KIR2DS2, KIR2DL2, KIR2DL5B, KIR2DS3, KIR3DS1,
KIR2DL5A, KIR2DS5, and KIR2DS1. Consequently, KIR A
haplotypes differ from each other predominantly on the
basis of KIR allelic polymorphism, while KIR B haplotypes
mainly by their gene content. Notably, although with different
frequencies, A and B haplotypes are maintained within all human
populations, strongly suggesting that they have distinct and
complementary functions and that they are under balancing
selection (46, 107, 108). Moreover, the peculiar structure of
KIR locus, including the presence of several genes sharing
exon/intron organization, having a high degree of homology,
and displaying the same orientation, facilitates non-reciprocal
recombination that promotes deletion or duplication of KIR
genes (i.e., formation of truncated or extended haplotypes), as
well as the generation of hybrid KIR genes (i.e., KIR alleles
including exons derived by different KIR genes) (Figure 1C)
(86, 87, 109–113).
KIR Allelic Polymorphism
As previously reported, the first KIR cDNA sequences have
been cloned in mid-90s. The great interest in the KIR field
led to the identification, at the present, of ∼1,000 alleles
(https://www.ebi.ac.uk/ipd/kir/). This extremely high level of
polymorphism, second only to that of HLA genes, arose from
studies including different populations and relatively simple
methodologies. Several allelic polymorphisms have been reported
to impact KIR protein expression and function. Indeed, the
presence of particular amino acid residues determining protein
misfolding and resulting in the lack of surface receptor expression
has been identified among KIR3DL1, KIR2DL1, and KIR2DL2
allotypes (95, 114–117). Moreover, KIR alleles characterized by
a termination codon causing the premature end of the protein
(namely KIRNull alleles) have been reported. Additionally, some
KIR2DL4 and KIR2DS4 alleles are characterized by nucleotide
deletions that, causing frameshift, lead to truncated polypeptides
(102, 118, 119). Notably, different clades of alleles coding
for surface receptors characterized by a low or high surface
expression have been detected in KIR3DL1 and KIR2DL1 genes
(95, 120, 121). Polymorphisms affecting KIR function may also
cause differences in ligand affinity or in signal transduction.
In this regard, it is well-established that KIR2DL1 allotypes
coded by Cen-A regions are stronger receptors than those
coded by Cen-B1 regions, and KIR2DL2 allotypes (coded by
Cen-B regions) have a higher ligand affinity than KIR2DL3
allotypes (coded by Cen-A regions) (116, 122). In addition,
the amino acid polymorphisms of KIR3DL1, the KIR receptor
displaying the highest level of allelic variation, have been shown
to impact not only its surface expression but also its affinity
for HLA class I Bw4 bearing allotypes (123–126). Different
amino acidic variations relevant for KIR signal transduction have
been also reported in the exons coding for the transmembrane
and cytoplasmic regions. In particular, the lack of charged
residues, important for its association with signal-transducing
polypeptides, has been described for a KIR2DS2 allele (127). In
KIR2DL1, polymorphisms in the exons of the cytoplasmic tail,
either causing the premature termination of translation at the
end of the transmembrane domain or affecting the strength of
inhibitory signal, have been reported (128, 129).
Thus, the extraordinary plasticity of the KIR gene family
and the variability due to both KIR gene content and allelic
polymorphismmake unlikely that unrelated individuals share the
same KIR genotype.
KIR/KIR-LIGAND PAIRS
As mentioned above, the HLA class I ligands recognized by
KIR2DL1, KIR2DL2/L3, KIR3DL1, and KIR3DL2 have been
identified almost conjointly with the characterization of the
receptors. Thereafter, the resolution of the crystal structures
of KIRs in complex with their ligands, the development
of several tools including soluble KIRs, KIR tetramers,
HLA class I tetramers folded with selected peptides, and
retrovirally transduced human cell lines (i.e., NKL, Jurkat)
expressing only one KIR, allowed to refine KIR/KIR-ligand
interactions (122, 130–134).
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FIGURE 1 | Gene organization of KIR locus. (A) A cartoon representation of the most frequent centromeric (Cen) and telomeric (Tel) regions detected in Caucasians.
(B) Schematic pictures of KIR gene order in the A haplotypes and in 3 representative B haplotypes. * indicates the hot spot of recombination. (C) Examples of an
extended and a truncated haplotype. Each colored box represents a KIR gene; for simplicity KIR gene names are reported in the boxes without the KIR acronym.
Inhibitory KIRs
In Figure 2, the molecular structure of the inhibitory KIRs
(iKIRs) and of their known cellular ligands is summarized.
Using KIR2DL1-Fc (i.e., chimeric molecules comprising the
extracellular portion of the receptor linked to the Fc region of
human IgG1) in multiplex HLA class I binding assays, it has
been possible to demonstrate that KIR2DL1 binds specifically,
and with high avidity, to all HLA-C C2 but not HLA-C C1 or any
HLA-A or HLA-B allotypes. The only exception is represented
by KIR2DL1∗022, a peculiar KIR2DL1 receptor carrying Lys44
(instead of Met44) that switches its ligand specificity to HLA-C
C1 (129). By the use of KIR2DL1-Fc and plasmon resonance,
it has been shown that several KIR2DL1 molecules recognize
distinct HLA-C C2 allotypes with different avidities (the highest
for HLA-C∗15:02 and the lowest for HLA-C∗04:01). As reported
in early studies, and as expected on the basis of the homology
in their extracellular domains, KIR2DL2 and KIR2DL3 bind a
similar set of HLA-C ligands. Again, using KIR-Fc molecules
it has been confirmed that KIR2DL2 and KIR2DL3 allotypes
recognize, at high affinity, HLA-C C1 bearing epitope, and
it has been demonstrated their ability to bind to two HLA-
B allotypes (i.e., HLA-B∗46:01 and HLA-B∗73:01) that, being
originated by crossing-over between HLA-C and HLA-B alleles,
conserve the C1 epitope. Moreover, KIR2DL2 and KIR2DL3
display the capability to bind HLA-C C2 allotypes, even though
with low affinity. Thus, in contrast to the simplicity of KIR2DL1
ligand recognition, a more complicated situation governs
KIR2DL2 and KIR2DL3 ligand interactions (116, 122). The only
known exception is represented by KIR2DL3∗005 that, differing
from other KIR2DL3 receptors, displays a HLA-C binding
ability similar to that observed for KIR2DL2 allelic products
(135). Increasing evidences indicate that both KIR2DL2/L3
and KIR2DL1, in addition to their ability to discriminate
between C1 and C2 epitopes, bind numerous peptide/HLA-C
combinations retaining a degree of peptide selectivity (136).
Generally, KIR2DL2 and KIR2DL3 are characterized by a greater
selectivity for peptide than KIR2DL1, and this ability seems to
be particularly relevant for the recognition of the low affinity
HLA-C C2 allotypes. Notably, the capability of KIR2DL1 to
recognize HLA-C∗08:02 (i.e., a HLA-C C1 allotype) presenting a
restricted number of peptides has been recently reported (137).
Taken together these studies underline how NK cells are able
to sense, not only the down-regulation of HLA class I, but also
alterations in HLA presented peptidome that may occur during
viral infections or malignant transformations.
Between the two D0-D2 receptors, KIR2DL4 is the only
one for which the ligand has been characterized. Differently
from other iKIR2D receptors, KIR2DL4 binds to HLA-G, a
non-classical HLA class I molecule that, in healthy cells, is
restricted to the trophoblast cells invading the maternal decidua
during early pregnancy. This receptor contains only one ITIM
in the long cytoplasmic tail and a charged residue in the
transmembrane region allowing its association with the γ chain
of FcεR. These features render this receptor a peculiar member
of the KIR family displaying an unusual hybrid structure and
sharing characteristics with both inhibitory and activating KIRs.
Functional studies revealed that KIR2DL4 is characterized by a
weak inhibitory potential and that its engagement with soluble
ligand results in strong cytokine release in the absence of killing
(138, 139).
It is well-established that KIR3DL1 binds not only to HLA-
B but also to some HLA-A Bw4 bearing allotypes. Indeed, it
has been reported that among Bw4pos HLA-A allotypes, HLA-
A∗24:02, -A∗32:01, -A∗23:01, but not HLA-A∗25:01, are able not
only to inhibit but also to educate KIR3DL1pos NK cells (140).
Among the five residues of α1 helix defining the Bw4 motif,
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FIGURE 2 | Schematic representation of the structure of iKIRs and their HLA
class I ligands. Each Ig domain is depicted as an oval and, according to its
structural features, labeled as D0, D1, and D2. Presence of ITIMs in KIR
cytoplasmic tails and ITAMs in FcεR γ chain is indicated with black and red Y,
respectively. The charged residue in KIR2DL4 transmembrane region is
reported as a red diamond. Each domain of HLA class I molecules is
represented as a colored circle and β2m as a brown circle. In HLA-C and
HLA-B molecules, K80, N80, T80, and I80 indicate the presence, at residue
80, of lysine, asparagine, threonine, and isoleucine, respectively.
the Ile/Thr dimorphism at residue 80 has been proposed as a
marker of KIR3DL1 ligand affinity. Recent studies clearly indicate
that, although many high affinity ligands possess Ile80 (Bw4 I80),
KIR3DL1/HLA Bw4pos allotype interactions are very complex
and strongly dependent on the avidity and surface expression of
both receptor and ligand. Indeed, functional analyses provided
clear evidences that both KIR3DL1 polymorphism and ligand
variability strongly affect the avidity of KIR/KIR-L combinations
sharply influencing NK cell function (123, 126, 141). As
previously mentioned, KIR3DL2 allotypes bind two HLA-A
allotypes (HLA-A∗03 and -A∗11) (71, 72). Functional analyses
revealed that this receptor is characterized by low inhibitory
capacity and its ligand interaction is highly dependent on the
HLA-A bound peptide (132). Recently, it has been demonstrated
that KIR3DL2 also recognizes the non-classical HLA class I
molecule HLA-F at open conformation (142). Another relevant
function of this iKIR is represented by its ability to function
as sensor for pathogen-associated molecular patterns. Indeed,
KIR3DL2 has been shown to bind CpG oligodeoxynucleotides
(ODNs), and its D0 domain is primarily involved in ODN
recognition (143). Remarkably, interaction between KIR3DL2
and ODN did not result in the delivery of inhibitory signals but
in a sharp down-modulation of its surface expression, and in the
induction of cytokine release underlining the antimicrobial role
of NK cells in the course of infection.
Activating KIRs
From a structural point of view, in addition to a short cytoplasmic
tail lacking ITIMs, a common feature of activating KIR (aKIRs)
is the presence, in their trasmembrane region, of a charged
residue (Lys) that allows their association with the signaling
adaptor protein KARAP/DAP12 containing immunoreceptor
tyrosine-based activating motifs (ITAMs) (144, 145). With the
exception of KIR2DS1, the aKIR ligands remained elusive for a
long time. Indeed, although the extracellular domains of some
aKIRs display a high sequence homology with those of some
iKIRs (namely, KIR2DS1-KIR2DL1, KIR2DS2-KIR2DL2, and
KIR3DS1-KIR3DL1 pairs), it has been difficult to demonstrate
aKIR/HLA class I interactions. Figure 3 shows the different
aKIR/ligand pairs identified so far.
The best characterized aKIR is KIR2DS1. Functional analyses
using in vitro expanded KIR2DS1pos NK cell clones, as well
as KIR2DS1 soluble receptor and KIR2DS1 tetramer binding
analyses, clearly demonstrated that this aKIR recognizes HLA-
C C2 allotypes, although with an affinity lower than that of
KIR2DL1 (i.e., its inhibitory counterpart) (62, 129, 146–149).
Moreover, using both site-directed mutagenesis approaches and
soluble receptors, it has been established that the residue at
position 70 (Lys70 or Arg70) sharply affects the ligand affinity
of KIR2DS1 molecules (146). Notably, a recent paper reported
that modulation of HLA-C by certain strains of HCMV is
required for a potent KIR2DS1-mediated NK cell activation. This
strongly suggests a role of this aKIR in viral recognition (150).
The HLA class I ligands recognized by KIR2DS2 have been
identified only recently, and they include HLA-C C1 allotypes
and HLA-A∗11:01 (133, 147, 151). Remarkably, this aKIR/KIR-
L interaction is highly peptide-dependent. In particular, the
capability of KIR2DS2 to directly recognize peptides from HCV
helicase presented by HLA-C∗01:02 (an HLA-C C1 allotype) may
explain, at least in part, the protective effect of this aKIR in
chronic hepatitis C infection (152). In addition, it has been also
reported that KIR2DS2 recognizes, on several human carcinoma
cell lines, a still undefined, β2m-independent cell surface protein
(153). Correlative studies reported that HIV-infected individuals
carrying both KIR3DS1 and HLA-B Bw4 I80 display slower
progression to AIDS and lower viral load. While these data could
suggest KIR3DS1 interaction with HLA-B Bw4 I80 allotypes, the
KIR3DS1 ligands have remained indefinite until recently, and
they are represented by the open conformation of the non-
classical HLA-F molecule and by the HLA-B∗51, an HLA-B Bw4
I80 allotype (154–156).
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FIGURE 3 | Schematic representation of the structure of aKIR and their HLA
class I ligand. Each Ig domain is depicted as an oval and, according to its
structural features, labeled as D0, D1, and D2. Presence of a charged residue
in the KIR transmembrane region and of ITAMs in DAP12 cytoplasmic tail is
indicated with orange diamond and orange Y, respectively. Each domain of
HLA class I molecules is represented as a colored circle and β2m as a brown
circle. In HLA-C and HLA-B molecules, K80, N80, and I80 indicate the
presence, at residue 80, of lysine, asparagine, and isoleucine, respectively.
KIR2DS3, KIR2DS4, and KIR2DS5 have no inhibitory
counterparts. Most likely because KIR2DS3 does not seem to
be expressed at the cell surface (157), it is still a receptor with
unknown function and unknown ligand. On the contrary, the
majority of KIR2DS4 and KIR2DS5 alleles code for surface
activating receptors (63, 158). KIR2DS4 binds a minority of
HLA-C allotypes carrying either C1 or C2 epitopes as well as
HLA-A∗11 (159). Recently, a highly peptide dependent ligand
recognition has been reported also for KIR2DS4. This aKIR
has been shown to recognize HLA-C∗05:01 presenting a peptide
derived from the highly conserved bacterial recombinase A, thus
providing evidence that it is involved in defense against bacterial
infections (160).
As previously reported, KIR2DS5 can be located either in
the centromeric half of some KIR haplotypes (i.e., Cen-B1
region) or in the telomeric half (namely Tel-B region). With
the only exception of KIR2DS5∗005, KIR2DS5 centromeric
alleles differ from the telomeric ones. Notably, four out of five
KIR2DS5 centromeric alleles but only two out of six KIR2DS5
telomeric alleles code for receptors recognizing several HLA-C
C2 molecules (161).
NK CELL EDUCATION AND
RECEPTOR REPERTOIRE
During their development, NK cells go through a process termed
“education,” involving the interaction between inhibitory NK
receptor (iNKR) and self HLA class I molecules. Although
different models have been proposed, a general rule for education
is that the strength of inhibitory interaction(s) dictates the
efficiency of NK effector function (12, 13, 162, 163). A prominent
role is played by the highly diversified system represented by
the combinations between inhibitory KIR with their KIR-L
(iKIR/KIR-L pairs). Another relevant iNKR is represented by the
CD94:NKG2A heterodimer, a type II protein belonging to the C-
type lectin superfamily, which recognizes the non-classical HLA
class I molecule HLA-E (10). Since HLA-E binds peptides cleaved
from the leader sequences (from −22 to −14 residues) of HLA-
A, -B, or -C, it has been generally considered as a sensor of the
overall amount of HLA class I molecules expressed on the cell
surface. Recently, the Met/Thr (M/T) dimorphism at position
−21 of the leader sequence of HLA-B (i.e., −21M and −21T)
has been described to strongly impact the CD94:NKG2A/HLA-
E interaction (164). Indeed, only a minority of HLA-B allotypes
having −21M can supply HLA-E binding peptides, while the
majority carrying −21T do not. Accordingly, individuals with
−21M HLA-B could show higher HLA-E expression and more
efficient NKG2Apos NK cells. The activating counterpart of
CD94:NKG2A is represented by CD94:NKG2C heterodimer,
which binds HLA-E as well, although with lower affinity.
Extremely variegated NK cell receptor repertoires can be
observed among different individuals (7, 60, 80, 164–167).
This diversity is primarily due to the high polymorphism of
KIR and HLA class I genes, which segregate independently,
leading to diverse compound genotypes (46). Another important
feature of the repertoire is the clonal distribution of KIR and
CD94:NKG2A. During education NK cells must engage at least
one iNKR with cognate HLA class I to become fully functional,
otherwise, they will be hypo-responsive. This process ensures
that each NK cell produced in the body maintains tolerance
to self. The hypothesis that NKR expression represents the
result of a stochastic event, in which the various encoding
genes are independently regulated, had been already discussed
in Alessandro’s review (7). From studies of NK cells at the
clonal level, it was clear that each NK cell could express either
one or more iNKR specific for self HLA (self-iNKR) as well as
additional iNKR specific for non-self HLA. The presence of NK
cells expressing a single self-iNKR confers an advantage to the
host, since it allows to sense the loss or peptide-induced alteration
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of even a single HLA class I allotype, and thus to kill the damaged
cell, through the mechanism of “missing self-recognition.”
While a strong interaction between iKIR and its KIR-L
positively impacts NK cell education, the behavior of aKIR is
opposite and induces down-regulation of NK cell responsiveness
in the presence of a strong cognate ligand. This phenomenon has
been described for KIR2DS1 and KIR3DS1. Thus, KIR2DS1pos
NK cells are anergic in HLA-C C2/C2 individuals, while they
are educated in C1/Cx ones (168). Similarly, KIR3DS1-mediated
positive recognition of HLA-B∗51 (Bw4 I80) could be detected in
NK cell clones derived from Bw4 I80 negative donors, but not in
those from Bw4 I80 positive donors (156).
Although genetics of KIR and HLA has the major impact
on the receptor repertoire of the circulating NK cell pool, also
environmental factors may play an important role. In this regard,
the phenotypic analysis of NK cells derived from twins, who are
genetically identical forKIR andHLA genes, has been particularly
relevant (169). Indeed, twins’ NK cell populations are similar
but not identical to each other, especially in adult age. In this
context, viral infections may impact the NK cell phenotype.
In particular, HCMV shapes the receptor repertoire, driving to
adaptive NK cell differentiation through epigenetic alterations
(170–173). Thus, the expanded NK cell subset is characterized by
the expression of CD94:NKG2C, mainly co-expressing KIR2DL
specific for self HLA-C allotypes, and CD57, a marker of
terminally differentiated stage (32, 33). Recent data revealed that
the expansion and differentiation of adaptive NKG2Cpos NK
cells could be determined by differentially recognition of distinct
HCMV strains encoding variable UL40 peptides (174).
Nowadays, new technologies allow the identification of
distinct subsets by the detection of multiple molecules in
the whole NK cell population, even freshly derived from
blood. Multi-parametric flow cytometry makes it possible the
simultaneous use of numerous mAbs, detecting the pattern
of different subpopulations carrying one or another iKIR,
aKIR, CD94:NKG2A, and CD94:NKG2C. Table 1 describes the
reactivity of some anti-KIRmAb, that can be used in combination
to dissect various iKIR and aKIR. Moreover, mass cytometry
by time-of-flight (CyTOF) technology allows the concomitant
assessment of more than 30 parameters, revealing that at least
30.000 and evenmore distinct PBNK phenotypes can be detected
in each individual (169).
NK cell education in pregnancy or in disease and the
particular KIR/HLA combinations associated with either a
protective role or a detrimental effect in placentation, infectious
diseases, autoimmune and inflammatory diseases, and in cancer
have recently been reviewed (46–48, 136, 175). Our group
studied NK cell education in disease, particularly focusing
on leukemia patients receiving HSCT (see below) or patients
with X-linked lymphoproliferative disease 1 (XLP1). XLP1 is
a primary immunodeficiency caused by mutations in SH2D1A,
the gene encoding the signaling lymphocyte activation molecule
(SLAM)-associated protein (SAP). Seminal studies coordinated
by Alessandro provided evidence that, in the absence of SAP, 2B4
and NTB-A (belonging to SLAM family) co-receptors associate
with protein tyrosine phosphatases thus delivering inhibitory
instead of activating signals (22, 24, 176). This specific immune
TABLE 1 | Some monoclonal antibodies recognizing KIR.
Clone Specificity Isotype Source§
143211 KIR2DL1/S5 IgG1 R&D
EB6B KIR2DL1/S1, KIR2DL3*005 IgG1 Our lab, Beckman Coulter
11PB6 KIR2DL1/S1, KIR2DL3*005 IgG1 Our lab, Miltenyi Biotec
HP-3E4 KIR2DL1/S1/S4 IgM BD Biosciences
HP-MA4 KIR2DL1/S1/S3/S5 IgG2b Biolegend, eBiosciences
GL183 KIR2DL2/L3/S2 IgG1 Our lab, Beckman Coulter
Y249 KIR2DL2/L3/S2 IgM Our lab
CH-L KIR2DL2/L3/S2 IgG2b BD Biosciences
DX27 KIR2DL2/L3/S2 IgG2a Biolegend, Miltenyi Biotec
ECM-41 KIR2DL3 (not *005 and *015) IgM Our lab
180701 KIR2DL3 (not *005 and *015) IgG2a R&D
1F12 KIR2DL3/S2 IgG2b C. Retière ∧
FES172 KIR2DS4 IgG2a Our lab, Beckman Coulter
PAX180 KIR2DS4 IgG1 Our lab
UP-R1 KIR2DL5 IgG1 Biolegend
DF200 KIR2DL1/L2/L3/S1/S2/S5 IgG1 Our lab
NKVSF1 Pan KIR2D IgG1 Miltenyi Biotec
Z27 KIR3DL1/S1 IgG1 Our lab, Beckman Coulter
DX9 KIR3DL1 IgG1 Miltenyi Biotec
Q66 KIR3DL2 IgM Our lab
AZ158 KIR3DL1/S1/L2 IgG2a Our lab
§The names of the vendor and/or the lab of production is indicated. “Our lab” means the
laboratories directed by A. Moretta, L. Moretta and M.C. Mingari.
∧C. Retiére: Etablissement Français du Sang-Pays de la Loire, Nantes, France.
dysfunction in XLP1 patients causes the inability of NK cells to
kill EBV-infected B cells (B-EBV), over-expressing their ligands
(i.e., CD48 and NTB-A), with dramatic clinical consequences.
Following this knowledge, we further analyzed the NK cell
receptor repertoire of these patients, showing that substantial
proportions of NK cells lacking any inhibitory receptor specific
for self-HLA (self-NKRneg) are present and are fully functional,
indicating that inhibitory 2B4 participates to NK cell education
(177). Remarkably, self-NKRneg NK cells can efficiently kill
CD48neg target cells, such as mature DC, with consequently
defective antigen presentation, further exacerbating the immune
defect of these patients.
INHIBITORY CHECKPOINTS IN NK CELLS
AND THEIR TARGETING IN
TUMOR THERAPY
As previously reported, the HLA class I specific inhibitory
receptors are constitutively expressed by NK cells and finely
regulate their function preventing NK-mediated damage to
healthy tissues and allowing the elimination of tumors displaying
defective HLA class I expression. Additional inhibitory
checkpoints are inducible and play a wider physiological role
in immune cell homeostasis. On the other hand, in tumors,
they may severely compromise NK-mediated responses and
promote tumor growth and metastasis. In particular, CTLA-4
and PD-1 are major regulators of immune responses and
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contribute to the maintenance of peripheral T cell tolerance.
PD-1, a member of the Ig-superfamily, was first identified in
T lymphocytes (178) and, more recently, in NK cells (44). In
cancer, upon binding to its ligands (PD-L1 and/or PD-L2)
expressed on tumor cells, PD-1 may impair the antitumor
cytotoxicity, thus favoring tumor immune escape. Human
PD-1bright NK cells have been detected in patients with CMV
infections and tumors (44, 179). For example, in ovarian
carcinoma patients, a sizable fraction of PD-1pos NK cells can
be detected in PB, while larger percentages are present in the
ascitic fluid of the same patients. Although PD-1 mRNA and
protein are detectable at the cytoplasmic level, the mechanisms
leading to its surface expression in human NK cells have
not been defined yet. The detection of PD-1pos in NK cells
associated to tumors suggests that signals delivered by the
tumor or its microenvironment may be involved in its surface
expression. Besides PD-1, several other inhibitory checkpoints
expressed by NK cells have been detected, and have been recently
reviewed (180). Briefly, CD96 and TIGIT belong to the same
family of the activating receptor DNAM-1 (their common
ligands, CD155 and CD112, are nectin-like molecules). TIGIT
was found to be up-regulated in tumor-associated NK cells
in colorectal cancer. KLRG1 is expressed by NK cells upon
activation (as well as by other lymphoid and myeloid cell types).
LAG-3 marks exhausted T cells infiltrating tumors, while its
possible modulatory effect on NK cells has not been defined
yet. TIM-3 binds primarily to Galectin-9 but also to other
tumor-associated antigens. A recently identified inhibitory
receptor which is likely to play an important role in controlling
NK cell activation, proliferation and function is IL-1R8, a
member of IL-1 receptor family and a component of the human
IL-37 receptor. Mice lacking IL1R8 do not develop carcinogen-
induced hepatocarcinoma (181). Thus, it is conceivable that
IL-1R8 blocking may unleash NK cells and promote efficient
antitumor responses.
PD-1/PD-L1 and Their Targeting in the
Therapy of Cancer
As mentioned above, PD-1 may impair T cell responses against
tumor cells. Importantly, immunotherapy with mAbs able
to disrupt the PD-1/PD-L1 interaction proved to be highly
effective, allowing unthinkable achievements in the cure of a
fraction of tumor patients. In this context, the number of
mAbs specific for PD-1 or PD-L1 approved for cancer therapy
is growing fast and the spectrum of tumors for which the
use of such agents is recommended includes non-small lung
cancer, melanoma, urothelial cancers, kidney tumors, Hodgkin
lymphoma, colorectal cancer, and hepatocellular carcinoma.
While the use of such checkpoint inhibitors represents a real
revolution in cancer treatment, in a still too large fraction of
patients these agents are ineffective. Accordingly, a major goal
is to predict the patient response to treatment, to avoid possible
side effects and useless high costs of the therapy. The expression
of PD-L1 on tumor cells undoubtedly represents a valuable
biomarker. However, its predictive value is still unsatisfactory
because of various limitations, including inter- and intra-
tumor heterogeneous PD-L1 expression, use of PD-1/PD-L1
specific mAbs displaying a substantially different reactivity (182),
different diagnostic material (biopsies vs. surgical specimens).
Patient selection criteria are being standardized, for example,
by defining the optimal number of biopsies that give results
comparable to the whole tumor section, considered as the gold
standard (183, 184). Given these limitations, research in progress
is aimed at identifying additional checkpoints possibly to be used
alone or in combination with PD-1/PD-L1 or CTLA-4.
Therapeutic Use of Anti-KIR or
Anti-NKG2A mAbs
After the launch of Innate-Pharma in Marseille, Alessandro’s
antibodies and his expertize were fundamental for the design
of a program focalized on NK cells harnessing the blockade of
inhibitory KIRs and NKG2A. Thus, three clinical grade mAbs
were produced: Lirilumab (also called IPH2101, formerly 1-7F9)
targeting KIRs, IPH4102 selectively recognizing KIR3DL2, and
Monalizumab targeting NKG2A. These reagents are currently
used in clinical trials to treat cancer patients. Thus, Lirilumab, a
first-in-class humanized IgG4 mAb directed against a common
epitope shared by KIR2D, disrupts the KIR/KIR-L interaction
by rendering NK cells “alloreactive” and allows killing of tumor
target cells. This antibody has been used in a phase I trial
in association with Lenalidomide, for NK stimulation, to treat
Multiple Myeloma. This combined treatment resulted to be
safe, tolerable, and associated with signs of clinical efficacy
(185). Because KIR3DL2 is highly expressed on cutaneous T cell
lymphomas, including mycosis fungoides and Sézary syndrome
(186), IPH4102 has been developed for the treatment of these
diseases. Phase I trials provided evidence that the treatment is
well-tolerated and efficacious. These encouraging results would
support the large-scale clinical trials (187).
Recent studies identified NKG2A as an important checkpoint
leading to remarkable antitumor effects in animal models
(188–190). Encouraging results have also been obtained in a
preliminary clinical trial in highly aggressive head and neck
cancers (188). Notably, NKG2A, constitutively expressed by NK
cells, can be induced also in T cells upon cytokine or antigen-
induced activation (191, 192). Indeed, previous in vitro studies
showed that mAb-mediated masking of NKG2A or KIRs, in
both polyclonal and clonal NK or T cell populations, induced
killing of HLA class Ipos tumor target cells (149, 188, 193–
195). Vivier group also showed that the antitumor effects of
anti-NKG2A mAb could be potentiated by the combined use
of other therapeutic mAbs (188). Based on the expression of
inhibitory checkpoint ligands on tumor cells, three therapeutic
approaches have been proposed: (1) HLA-Epos tumors lacking the
expression of other ligands for inhibitory checkpoints or tumor
antigens: blocking of NKG2A could unleash both NK- and T-
cell-mediated antitumor responses in amurinemodel; (2) tumors
expressing both HLA-E and PD-L1: by the combined blocking
of NKG2A and PD-1/PD-L1 axis, not only enhancement of NK
and T cell cytotoxicity but also induction of T cell proliferation
and establishment of T cell memory were detected; (3) tumors
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expressing HLA-E and specific tumor antigens (e.g., EGF-R):
blockade of NKG2A increased the efficacy of anti-EGF-R by
allowing a CD16-mediated efficient ADCC by mature, highly
cytotoxic NK cells.
KIR AND HAPLOIDENTICAL
HEMATOPOIETIC STEM
CELL TRASPLANTATION
The discovery of both HLA class I specific inhibitory receptors
and NK cell alloreactivity has been exploited, after a relatively
short time interval, for the treatment of acute, high-risk
leukemia in the haplo-HSCT setting. HSCT is the life-saving
therapy for such leukemia with adverse molecular or cytogenetic
characteristics, or with poor response to chemotherapy, or
relapsing. However, an HLA 10/10 allelic matched donor,
whether sibling or unrelated, is available only for two out
of three patients, and this proportion can be even lower for
patients belonging to certain ethnic groups. Thus, haplo-HSCT
has been developed in the attempt to rescue these patients
(196). In such transplantation setting, donor derived NK cells
are defined as “alloreactive” when they express, as inhibitory
receptor, exclusively KIR(s) specific for self-HLA class I allele(s)
(KIR-L), allowing the elimination of patient cells missing that
particular KIR-L. A seminal study by Ruggeri et al. (197) reported
a 5-year survival probability of ∼60% in adult AML patients in
case of donor NK alloreactivity (KIR/KIR-L mismatch in graft
vs. host direction), while survival was <5% in its absence. In
2002, Alessandro and some authors of the present contribution
started a fruitful collaboration with Franco Locatelli, first at the
University of Pavia and subsequently at the Ospedale Pediatrico
Bambino Gesù in Roma (149, 198). In these studies, patients
were represented by children and young adults (1–20 years) with
acute high-risk ALL or AML.Notably, in the haplo-HSCT setting,
most pediatric patients find an available donor, represented by
one parent.
KIR-Based Donor Selection
In view of the major relevance of NK alloreactivity, a great
attention was paid by our group to the selection of the best
possible donor, based primarily on the “perfect mismatch”
(199) and on the size of alloreactive NK cell subset. To this
end, a reliable method was developed to define the presence
and the frequency of such subpopulation in potential donors
(149). This is based on combined genotypic and phenotypic
analyses to assess (i) the presence in the donor of KIR-L(s)
absent in the recipient, (ii) donor’s KIR genotype to evaluate the
presence of KIR(s) specific for the mismatched KIR-L(s), and
(iii) identification of the alloreactive subset using appropriate
anti-KIR and anti-NKG2A mAb combinations (198). Leukemia
patients, after the conditioning regimen, receive very high
numbers (“megadoses”) of highly purified T-depleted CD34pos
cells, isolated either from bone marrow (BM) or PB. Isolation
from PB is preceded by donor treatment with G-CSF in order
to “mobilize” CD34pos cells from BM. Notably, different from
AML, adult high-risk ALL were poorly responding to haplo-
HSCT even in the presence of donor NK alloreactivity. Thus,
it was somewhat surprising to find opposite results in pediatric
patients. Indeed, in case of NK alloreactivity, the survival rate was
∼70% in ALL and ∼40% in AML, while in the absence of NK
alloreactivity, the percentages were ∼35 and ∼20%, respectively.
Of note, in the transplantation setting with “pure CD34pos”
cells, most deaths due to leukemia relapses or transplant-
related mortality occurred early, within few weeks/months after
transplantation. As mentioned above, NK cells, during their
differentiation from HSC, first express CD94:NKG2A, while KIR
are acquired only at later stages. Accordingly, the generation
of alloreactive, mature NK cells requires a relatively long time
interval (6–8 weeks). Thus, for several weeks, the absence of
mature (alloreactive) NK cells together with the absence of
adaptive immunity may be critical for the control of leukemia
relapses and infections. The survival rate of leukemia patients
receiving a CD34pos haplo-HSC could be considered satisfactory
in view of the extremely poor prognosis of patients not receiving
transplantation. However, the delayed appearance of alloreactive
NK cells, conceivably explaining the occurrence of early relapses
and infections, suggested, in 2010, the application of a new graft
manipulation based on the depletion of αβ T lymphocytes and
CD19pos B lymphocytes. Thanks to this novel approach, the
graft infused contains, besides HSC, other cell types, including
intermediate precursors (CD34neg), various myeloid cell types,
mature NK cells, and γδ T lymphocytes. Notably, both NK and
γδ T lymphocytes may exert a potent anti-leukemia activity and
contribute to the control of infections. Accordingly, patients
could immediately benefit of high numbers (30–40 × 106/kg)
of donor mature NK cells and γδ T cells (3–5 × 106/kg). The
clinical outcome in 80 children was excellent with an overall
survival of ∼70% not only in ALL, but also in AML (200).
Surprisingly, NK alloreactivity did not appear to play a relevant
role in the clinical outcome. The marked improvement of the
survival rate in the absence of alloreactivity may be due, at
least in part, to the additional selection criteria progressively
applied to identify the most suitable among the available
donors. These include the following positive characteristics: (i)
KIR B/X genotype, (ii) HLA-C1pos/KIR2DS1pos for HLA-C2pos
recipients, (iii) high absolute cell numbers of NK and γδT
lymphocytes, and (iv) high expression of NKp46 and presence
of NKG2C (198, 200). The presence of mature NK and γδ T
from the beginning of the transplantation and their persistence
in the recipient as efficient immune cells, due to the lack of
GvHD prophylaxis, can explain the successful clinical results.
In immunocompromised patients undergoing allogeneic HSCT,
HCMV infection/reactivation frequently occurs (201). Several
studies documented a role of HCMV in promoting rapid NK
cell maturation and in the selective expansion of NKG2Cpos
adaptive NK cells (34, 202, 203). This HCMV related effect
on NK cell repertoire was also observed in pediatric patients
receiving αβ T/B cell-depleted haplo-HSCT (204). Remarkably,
a study revealed that, in NKG2Cneg/neg umbilical cord blood
donors, HCMV infection promoted a maturation and expansion
of NK cells expressing aKIRs (205). These findings suggest
that, in the absence of NKG2C, aKIRs may sense HCMV
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infection and promote selective expansion of mature aKIRpos
NK cells, underscoring the concept that aKIRs may sense
microbial infections.
Taken together, the clinical results in haplo-HSCT indicate
that cells belonging to innate immunity play a crucial role in
the cure of patients with otherwise lethal leukemia and provide
a solid background to further improve the survival rate and to
implement novel NK-based therapies (e.g., CAR-NK). In this
context, helper ILC, primarily ILC-3, may provide a tool to
further improve early innate defense against pathogens after
HSCT. Notably, it has been shown that ILC-3 development may
be favored by given sources of HSC for transplantation (206).
CONCLUDING REMARKS
There is little doubt that major advances in immunology and
the exploitation of fundamental discoveries offered invaluable
tools for the therapy of cancer. Indeed, the recent years witnessed
unprecedented successes in the cure of different, high aggressive
tumors and leukemia. In this context, NK cells and their receptors
were shown to play an unexpected role. Thus, the discovery
of KIRs provided the molecular basis for haplo-HSCT, which
allowed the cure of patients with acute, high-risk leukemia for
whomnoHLA-compatible donors were available. These data also
provided the first evidence that not only T and B lymphocytes,
but also cells of the innate immunity may be exploited for
tumor therapy. While checkpoint inhibitors targeting PD-1 or
CTLA-4 represent the most effective tools to successfully treat a
fraction of otherwise incurable cancer patients, their combined
use with therapeutic antibodies blocking NKG2A and KIR may
further extend the benefit to a large proportion of patients.
Thus, the Alessandro’s legacy, besides unraveling the molecular
mechanisms of NK cell function, also extends to thousands of
leukemia patients recovered from their otherwise fatal disease.
The continuous interest and evolution on KIR research is
also witnessed by the organization of a KIR Workshop taking
place every year and a half, allowing to share the most recent
advances on KIRs in health and disease, with a fruitful exchange
of ideas and knowledge in a friendly atmosphere. Last October,
the KIR Workshop 2018 has been organized by our group, and
Alessandro had begun to collaborate with us on its organization
and realization. This meeting was dedicated to Alessandro.
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